Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Coley reports encouraging phase I results in hepatitis
Actilon is a first-in-class Toll-like receptor 9 (TLR9) agonist initially being developed for the treatment of hepatitis C. The phase Ia trial of Actilon in 40 healthy volunteers
Actilon is a first-in-class Toll-like receptor 9 (TLR9) agonist initially being developed for the treatment of hepatitis C. The phase Ia trial of Actilon in 40 healthy volunteers
Traficet-EN is a novel, orally bioavailable, anti-inflammatory agent that targets the chemokine receptor known as CCR9. The receptor is on gut-homing inflammatory cells that are responsible for the
The data, published by researchers collaborating with Biorex R&D Company (the company from which CytRx purchased iroxanadine), demonstrated that iroxanadine protects human endothelial cells that line the walls
Rotarix is an oral, two-dose, live attenuated vaccine against rotavirus disease in infants that was licensed in 1997 by Avant Immunotherapeutics to GSK for worldwide commercialization. Rotavirus infection
Detailed financial terms were not disclosed, but include upfront, annual and milestone payments, all in cash, and royalties on sales of any products that result from the licensing
GX15-070 is a novel, targeted cancer treatment designed to induce apoptosis (natural cell death) by inhibiting the Bcl-2 family of proteins, one of the most validated and well-studied
The open-label, dose-escalation study conducted at two major cancer treatment centers is designed to evaluate the safety and tolerability of the small molecule Aurora kinases inhibitor VX-680 when
Echelon’s product pipeline is focused on the rapidly emerging field of transduction signalling technology. It has early therapeutic leads (mostly direct PI3K inhibitors) against some forms of cancer
Tamoxifen is a cytostatic oestrogen receptor antagonist used extensively for the treatment of hormonally sensitive breast cancer. Soltamox is the only oral liquid presentation of tamoxifen licensed in
The drug candidate, PA-457, is the first in a new class of HIV drugs called maturation inhibitors. In granting fast track status for the form of PA-457 that